Graded defects in cytotoxicity determine severity of hemophagocytic lymphohistiocytosis in humans and mice
Abstract: Primary hemophagocytic lymphohistiocytosis (HLH) is a life-threatening disease of hyperinflammation resulting from immune dysregulation due to inherited defects in the cytolytic machinery of natural killer and T cells. In humans, mutations in seven genes encoding proteins involved in cytolytic effector functions have so far been identified that predispose to HLH. However, although most affected patients develop HLH eventually, disease onset and severity are highly variable. Due to the genetic heterogeneity and variable time and nature of disease triggers, the immunological basis of these variations in HLH progression is incompletely understood. Several murine models of primary HLH have been established allowing to study HLH pathogenesis under more defined conditions. Here we directly compare the clinical HLH phenotype in six HLH-prone mouse strains with defects in the granule-dependent cytotoxic pathway. A severity gradient of HLH manifestations could be identified that is defined by the genetically determined residual lytic activity of cytotoxic T lymphocytes (CTL) and their ability to control lymphocytic choriomeningitis virus, which was used as a trigger for disease induction. Importantly, analysis of cohorts of HLH patients with severe bi-allelic mutations in the corresponding genes yielded a similar severity gradient in human HLH as reflected by the age at disease onset. Our findings define HLH as a threshold disease determined by subtle differences in the residual lytic activity of CTL
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
Frontiers in immunology. - 4 (2013) , 00448, ISSN: 1664-3224
- Ereignis
-
Veröffentlichung
- (wo)
-
Freiburg
- (wer)
-
Universität
- (wann)
-
2019
- Urheber
-
Jessen, Birthe
Kögl, Tamara
Sepulveda, Fernando E.
Saint Basile, Genevieve de
Aichele, Peter
Ehl, Stephan
- DOI
-
10.3389/fimmu.2013.00448
- URN
-
urn:nbn:de:bsz:25-freidok-1146485
- Rechteinformation
-
Kein Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:25 MESZ
Datenpartner
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Jessen, Birthe
- Kögl, Tamara
- Sepulveda, Fernando E.
- Saint Basile, Genevieve de
- Aichele, Peter
- Ehl, Stephan
- Universität
Entstanden
- 2019
Ähnliche Objekte (12)
Disease pathophysiology in murine models of primary hemophagocytic lymphohistiocytosis: triggers and effectors
Cell versus cytokine – directed therapies for hemophagocytic lymphohistiocytosis (HLH) in inborn errors of immunity
Adoptive T cell therapy cures mice from active hemophagocytic lymphohistiocytosis (HLH)
Adoptive T cell therapy cures mice from active hemophagocytic lymphohistiocytosis (HLH)
T-cell gene therapy for perforin deficiency corrects cytotoxicity defects and prevents hemophagocytic lymphohistiocytosis manifestations
Immune‐mediated pathology as a consequence of impaired immune reactions: the IMPATH paradox
Trigger‐dependent differences determine therapeutic outcome in murine primary hemophagocytic lymphohistiocytosis
Trigger‐dependent differences determine therapeutic outcome in murine primary hemophagocytic lymphohistiocytosis
The microbiome modifies manifestations of hemophagocytic lymphohistiocytosis in perforin‐deficient mice
Autoimmune lymphoproliferative immunodeficiencies (ALPID) in childhood: breakdown of immune homeostasis and immune dysregulation
Immune‐mediated pathology as a consequence of impaired immune reactions: the IMPATH paradox
Autoimmune lymphoproliferative immunodeficiencies (ALPID) in childhood: breakdown of immune homeostasis and immune dysregulation
Disease pathophysiology in murine models of primary hemophagocytic lymphohistiocytosis: triggers and effectors
Cell versus cytokine – directed therapies for hemophagocytic lymphohistiocytosis (HLH) in inborn errors of immunity
Adoptive T cell therapy cures mice from active hemophagocytic lymphohistiocytosis (HLH)
Adoptive T cell therapy cures mice from active hemophagocytic lymphohistiocytosis (HLH)
T-cell gene therapy for perforin deficiency corrects cytotoxicity defects and prevents hemophagocytic lymphohistiocytosis manifestations
Immune‐mediated pathology as a consequence of impaired immune reactions: the IMPATH paradox
Trigger‐dependent differences determine therapeutic outcome in murine primary hemophagocytic lymphohistiocytosis
Trigger‐dependent differences determine therapeutic outcome in murine primary hemophagocytic lymphohistiocytosis
The microbiome modifies manifestations of hemophagocytic lymphohistiocytosis in perforin‐deficient mice
Autoimmune lymphoproliferative immunodeficiencies (ALPID) in childhood: breakdown of immune homeostasis and immune dysregulation
Immune‐mediated pathology as a consequence of impaired immune reactions: the IMPATH paradox
Autoimmune lymphoproliferative immunodeficiencies (ALPID) in childhood: breakdown of immune homeostasis and immune dysregulation
Disease pathophysiology in murine models of primary hemophagocytic lymphohistiocytosis: triggers and effectors
Cell versus cytokine – directed therapies for hemophagocytic lymphohistiocytosis (HLH) in inborn errors of immunity
Adoptive T cell therapy cures mice from active hemophagocytic lymphohistiocytosis (HLH)
Adoptive T cell therapy cures mice from active hemophagocytic lymphohistiocytosis (HLH)
T-cell gene therapy for perforin deficiency corrects cytotoxicity defects and prevents hemophagocytic lymphohistiocytosis manifestations
Immune‐mediated pathology as a consequence of impaired immune reactions: the IMPATH paradox
Trigger‐dependent differences determine therapeutic outcome in murine primary hemophagocytic lymphohistiocytosis
Trigger‐dependent differences determine therapeutic outcome in murine primary hemophagocytic lymphohistiocytosis
The microbiome modifies manifestations of hemophagocytic lymphohistiocytosis in perforin‐deficient mice
Autoimmune lymphoproliferative immunodeficiencies (ALPID) in childhood: breakdown of immune homeostasis and immune dysregulation
Immune‐mediated pathology as a consequence of impaired immune reactions: the IMPATH paradox